1. Home
  2. CNS vs SUPN Comparison

CNS vs SUPN Comparison

Compare CNS & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Inc

CNS

Cohen & Steers Inc

HOLD

Current Price

$74.75

Market Cap

3.7B

Sector

Finance

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$44.40

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNS
SUPN
Founded
1986
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.0B
IPO Year
2004
2010

Fundamental Metrics

Financial Performance
Metric
CNS
SUPN
Price
$74.75
$44.40
Analyst Decision
Hold
Strong Buy
Analyst Count
2
5
Target Price
$71.50
$61.60
AVG Volume (30 Days)
200.1K
536.4K
Earning Date
04-16-2026
05-05-2026
Dividend Yield
3.96%
N/A
EPS Growth
N/A
N/A
EPS
0.82
N/A
Revenue
$427,536,000.00
$392,755,000.00
Revenue This Year
$4.71
$22.70
Revenue Next Year
$4.37
$19.14
P/E Ratio
$91.01
N/A
Revenue Growth
4.07
N/A
52 Week Low
$58.39
$31.16
52 Week High
$78.81
$59.68

Technical Indicators

Market Signals
Indicator
CNS
SUPN
Relative Strength Index (RSI) 56.66 40.36
Support Level $59.88 $43.67
Resistance Level $78.69 $52.36
Average True Range (ATR) 2.05 1.43
MACD 0.02 0.01
Stochastic Oscillator 64.29 46.73

Price Performance

Historical Comparison
CNS
SUPN

About CNS Cohen & Steers Inc

Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for around two-thirds of its $98.4 billion in managed assets at the end of February. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (25%) of its managed assets (base management fees) from institutional clients, 48% (55%) from open-end funds, and 13% (20%) from closed-end funds.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Share on Social Networks: